• LinkedIn Social Icon
  • Twitter Social Icon

© 2016-2017 by Virtuvax BV, The Netherlands

Our Team
Ernst Soethout, CEO

E.Soethout[at]virtuvax.nl 

Phone: +31 6 29 89 47 29

Dr. Ernst Soethout DVM, received a PhD in immunology from Utrecht University, had positions of increasing gravity at the Netherlands Vaccine Institute in R&D and was finally responsible for business development, intellectual property and licensing at Intravacc, the national institute for vaccine research of the Netherlands. Dr. Soethout authored multiple scientific papers, became inventor on 3 patents, designed global development projects in which biotech companies and big pharma collaborated and managed research projects involving multiple partners from various continents. Dr. Soethout closed deals worth >M € with biotech industry and big pharma and was advisor to EMA, London for marketing authorization of vaccines.sed EMA for marketing authorization of vaccines.

Virtuvax B.V. is headed by Ernst Soethout, DVM PhD. Having extensive experience in pharmaceutical research, vaccine development and business development, we strive to make the best possible technology available to our clients and for this we make use of our extensive network in the vaccine industry, governments and the academic field.

  • LinkedIn Social Icon
  • Twitter Social Icon

Virtuvax is a full service vaccine development and marketing company. We help our customers to get their vaccine technology developed, transferred and put into practice. Thereto we make use of the combined strengths of companies, institutes and universities. Our characteristics are:

  • Established in 2016

  • Headed by experts in vaccine development

  • Collaborating with selected companies, institutes and universities which are all champions in cinology

  • Serving biotech companies that aim to have their technology taken further until it will have gained significant value

  • Serving vaccine manufacturers aiming to expand their product portfolio with biosimilar or novel vaccines

  • Serving big pharma and pharmaceutical companies aiming to acquire novel top-notch vaccine technology

  • Assisting health authorities to improve vaccination policies

 

Our focus area covers the complete pathway of vaccine development from conception until end-clinical, the transfer of vaccine technology and the associated business development.

Virtuvax was founded in January 2016. We specialize in development and transfer of vaccine technology as well as business development. Acting out of the belief that multidisciplinary cooperation of experts is key for the development of new vaccines, we strategically cooperate with partners offering the best possible solutions for the development of a new product. Our approach is to create a virtual platform in which all parties collaborate, ultimately until market authorization.

Company

Who we are

 
Our fundamentals

Our company is based on two basic principles. First, we believe in the virtues of excellent partnership and superior expertise for the development of vaccines. Second, we believe that major steps are taken when experts from different disciplines collaborate to take one specific technology forward. To bring these expert parties together, we create a virtual enterprise for each vaccine technology that we develop. Hence, we named our company Virtuvax, representing the very essentials of vaccine development we count on. We aim to become the largest and most successful company applying the model of virtual collaboration in the vaccine industry.